Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Douglas L. Arnold et al.|The Lancet Neurology|2021Cited by 192
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patientsDaniel Whittam, Brigitte Wildemann, Álvaro Cobo‐Calvo et al.|Multiple Sclerosis and Related Disorders|2020Cited by 179
G-computation, propensity score-based methods, and targeted maximum likelihood estimator for causal inference with different covariates sets: a comparative simulation studyArthur Chatton, Yohann Foucher, Florent Le Borgne et al.|Scientific Reports|2020Cited by 126
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisMathilde Lefort, F. Grand’Maison, Sifat Sharmin et al.|BMC Medical Research Methodology|2022Cited by 6
Consensus d’experts francophones sur la progression insidieuse de la sclérose en plaques : physiopathologie, mesures et besoins non couverts associésDavid Laplaud, Patrick Vermersch, de Sèze et al.|Revue Neurologique|2024Cited by 0